Phuong Wirths, DO
Family Medicine · Curwensville, PANPI 1164457263
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$899
- Pfizer$752
- AstraZeneca$738
- Lilly USA, LLC$610
- AbbVie$576
- Novartis$371
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,39599%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $899 |
| Pfizer | 58 | $752 |
| AstraZeneca | 41 | $738 |
| Lilly USA, LLC | 33 | $610 |
| AbbVie(2 entities) | 33 | $576 |
| Novartis | 17 | $371 |
| Johnson & Johnson | 23 | $329 |
| Boehringer Ingelheim | 20 | $263 |
| Sunovion Pharmaceuticals Inc. | 11 | $222 |
| Teva Pharmaceuticals USA, Inc. | 15 | $195 |
| Amarin Pharma, Inc. | 11 | $177 |
| Abbott | 9 | $156 |
| Exact Sciences | 7 | $131 |
| GSK | 9 | $129 |
| Merck | 8 | $125 |
| Astellas Pharma US Inc | 6 | $105 |
| Bayer | 6 | $90 |
| Tactile Systems Technology Inc | 5 | $85 |
| Amgen | 5 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $78 |
| Phathom Pharmaceuticals, Inc. | 5 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Nestle Healthcare Nutrition Inc. | 3 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$121
How this compares
$6,442 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 144 | $97,930 |
| OzempicSemaglutide | 70 | $76,187 |
| TrulicityDulaglutide | 40 | $46,640 |
| FarxigaDapagliflozin Propanediol | 52 | $42,501 |
| XareltoRivaroxaban | 44 | $27,838 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $24,866 |
| JanuviaSitagliptin Phosphate | 30 | $24,460 |
| JardianceEmpagliflozin | 31 | $21,791 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $11,923 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,202 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $9,248 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $4,462 |
| Levothyroxine Sodium | 310 | $3,570 |
| Atorvastatin Calcium | 257 | $2,839 |
| Simvastatin | 213 | $2,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $752 | $97,930144 claims |
| Novo NordiskOzempic | $899 | $76,18770 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $129 | $46,99187 claims |
| Lilly USA, LLCTrulicity | $610 | $46,64040 claims |
| AstraZenecaFarxiga | $738 | $42,50152 claims |
| Johnson & JohnsonXarelto | $329 | $27,83844 claims |
| MerckJanuvia | $125 | $24,46030 claims |
| Boehringer IngelheimJardiance | $263 | $21,79131 claims |
| AbbVieSynthroid | $576 | $2,19535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Curwensville
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.